Metformin Immediate and Extended-Release Adverse Events and Effects on Metabolic Parameters: A Meta-Analysis
Life Sciences -Medicine
DOI:
https://doi.org/10.22376/ijlpr.2023.13.4.L173-L181Keywords:
Metformin immediate-release, extended-release, HbA1c, lipid profile, adverse events.Abstract
Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar from inception until September 2022. Studies were eligible if they were randomized controlled trials and compared metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. The keywords used were metformin immediate-release, extended-release, glycated hemoglobin, HbA1c, high-density lipoproteins, low-density lipoproteins triglycerides, total cholesterol, adverse effects, and side effects. The retrieved data were exported to an Excel sheet detailing the authors' names, the country of origin of the study, the number of patients and control subjects, and the total number of events in the interventional and control groups. No significant statistical difference was found between metformin immediate-release and metformin extended-release regarding the reduction of HbA1c, overall adverse effects, low-density lipoproteins, and high-density lipoproteins; odd ratio, 0.08, 95% CI, -0.14-0.29; 1.34, 95% CI, 0.86-2.08; -0.03, 95% CI, -0.22-0.17; and -0.26, 95% CI, -1.32-0.80 respectively. Metformin immediate-released reduced total cholesterol better than the extended-release; odd ratio, -2.35, 95% CI, -2.57-2.12. However, a paradox was observed regarding triglycerides (increment on extended-release and reduction with extended-release); odd ratio, -0.36, 95% CI, -0.44-0.28. No significant differences were found between the two formulations except for a better triglyceride reduction and total cholesterol in the immediate-release arm. Keywords: , , , ,
References
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107-11. doi: 10.2991/jegh.k.191028.001, PMID 32175717.
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional, and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119, PMID 34879977.
Aggarwal N, Singla A, Mathieu C, Montanya E, Pfeiffer AFH, Johnsson E, et al. Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):463-7. doi: 10.1111/dom.13104, PMID 28857388.
Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123(1):15-23. doi: 10.3810/pgm.2011.01.2241, PMID 21293080.
Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017;130:163-70. doi: 10.1016/j.diabres.2017.06.011, PMID 28646699.
Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44(7):721-9. doi: 10.2165/00003088-200544070-00004, PMID 15966755.
Derosa G, D’Angelo A, Romano D, Maffioli P. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Des Devel Ther. 2017;11:1481-8. doi: 10.2147/DDDT.S131670, PMID 28553078.
Tabesh M, Hachem M, Lau LH, Borschmann K, Churilov L, Price SAL, et al. Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomized open blinded endpoint controlled trial. J Clin Neurosci. 2021;86:103-9. doi: 10.1016/j.jocn.2021.01.006, PMID 33775312.
Yuxin H, Cuiping J, Wen T, Jieyuzhen Q, Xiaoming T, Qin G, et al. Comparison of gastrointestinal adverse events with different doses of metformin in the treatment of elderly people with type 2 diabetes. J Clin Pharm Ther. 2020;45(3):470-6. doi: 10.1111/jcpt.13087, PMID 31769886.
Hermans MP, Ahn SA, Rousseau MF. What is the phenotype of patients with gastrointestinal intolerance to metformin? Diabetes Metab. 2013;39(4):322-9. doi: 10.1016/j.diabet.2013.05.005, PMID 23786968.
Mariye T, et al. Determinants of poor glycemic control among diabetes mellitus patients in public hospitals of the central zone, Tigray, North Ethiopia, 2018: unmatched Case-Control Study. Endocrinol Metab. 2020;4(2).
Yosef T, Nureyev D, Tekalign E. Poor glycemic control and it's contributing factors among type 2 diabetes patients at Adama Hospital Medical College in East Ethiopia. Diabetes Metab Syndr Obes. 2021;14:3273-80. doi: 10.2147/DMSO.S321756, PMID 34290512.
Franco RS. The measurement and importance of red cell survival. Am J Hematol. 2009;84(2):109-14. doi: 10.1002/ajh.21298, PMID 19025796.
Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Curr Pharm Des. 2017;23(17):2532-50. doi: 10.2174/1381612822666161201152941, PMID 27908266.
Tan J, Wang Y, Liu S, Shi Q, Zhou X, Zhou Y, et al. Long-acting metformin vs. metformin immediate release in patients with type 2 diabetes: a systematic review. Front Pharmacol. 2021;12:669814. doi: 10.3389/par.2021.669814, PMID 34079464.
Gao H, Xiao W, Wang C, Zhang J, Yang Y, Yang J, et al. The metabolic effects of once-daily extended‐release metformin in patients with type 2 diabetes: a multicentre study. Int J Clin Pract. 2008;62(5):695-700. doi: 10.1111/j.1742-1241.2008.01733.x, PMID 18412932.
Hameed M, Khan K, Salman S, Mehmood N. Dose comparison and side effect profile of metformin extended release versus metformin immediate release. J Ayub Med Coll Abbottabad. 2017;29(2):225-9. PMID 28718236.
Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, et al. Improved glycemic control with minimal systemic metformin exposure: effects of metformin Delayed-Release (metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLOS ONE. 2018;13(9):e0203946. doi: 10.1371/journal.pone.0203946, PMID 30252913.
Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin levels in patients with type 2 diabetes mellitus. Metabolism. 2007;56(8):1087-92. doi: 10.1016/j.metabol.2007.03.018, PMID 17618954.
Ji L, Liu J, Yang J, Li Y, Liang L, Zhu D, et al. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial. Diabetes Obes Metab. 2018;20(4):1006-13. doi: 10.1111/dom.13190, PMID 29227571.
Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4):759-64. doi: 10.2337/diacare.29.04.06.dc05-1967, PMID 16567811.
Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565-72. doi: 10.1185/030079904125003278, PMID 15119994.
Zhang JP, Yang WY, Hong TP, Yang JK, Xiao WH, Gao HW, et al. Efficacy and safety of extended-release metformin in the treatment of type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi. 2007;87(18):1238-40. PMID 17686255.
Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515-29. doi: 10.1016/s0149-2918(03)80093-0, PMID 12749511.
Ghorpade V, Hiray R, Daswani B, Ghongane B. Comparison of conventional and sustained-release formulation of metformin in type 2 diabetics. Int J Basic Clin Pharmacol. 2016;5:274-80. doi: 10.18203/2319-2003.ijbcp20160654.
McGuire H, Longson D, Adler A, Farmer A, Lewin I, Guideline Development Group. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ. 2016;353:i1575. doi: 10.1136/bmj.i1575, PMID 27052837.
Tarry-Adkins JL, Grant ID, Ozanne SE, Reynolds RM, Aiken CE. Efficacy and side effect profile of different formulations of metformin: a systematic review and meta-analysis. Diabetes Ther. 2021;12(7):1901-14. doi: 10.1007/s13300-021-01058-2, PMID 34075573.
Little RR, Rohlfing CL. The long and winding road to optimal HbA1c measurement. Clin Chim Acta. 2013;418:63-71. doi: 10.1016/j.cca.2012.12.026.
Svensson E, Baggesen LM, Johnsen SP, Pedersen L, Nørrelund H, Buhl ES et al. Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 metformin initiators. Diabetes Care. 2017;40(6):800-7. doi: 10.2337/dc16-2271, PMID 28404659.
Abrilla AA, Pajes ANNI, Jimeno CA. Metformin extended-release versus metformin immediate-release for adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2021;178:108824. doi: 10.1016/j.diabres.2021.108824, PMID 33887354.
Sheikhy A, Eydian Z, Fallahzadeh A, Shakiba M, Hajipour M, Alaei M et al. Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial. J Pediatr Endocrinol Metab. 2022;35(4):505-10. doi: 10.1515/jpem-2021-0704, PMID 35249270.
Kiałka M, Gałuszka-Bednarczyk A, Wajda A, Czekańska P, Zdzierak B, Mrozińska S et al. Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome. Przegl Lek. 2017;74(4):144-6. PMID 29696950.
Dienstmann G, Nascimento IBD, Sales WB, Leite Ramos de Souza M, Silva GDD, de Oliveira LC et al. No effect of a low dose of metformin on the lipid profile, body mass index, and weight gain in pregnant women with obesity: A randomized trial. Obes Res Clin Pract. 2020;14(6):561-5. doi: 10.1016/j.orcp.2020.09.005, PMID 33008770.
Quintero-Castillo D, Luz-Araujo H, Guerra-Velázquez M, Reyna-Villasmil E, Santos Bolívar JS, Torres-Cepeda D et al.. Lipid profile in obese and non-obese women with polycystic ovary syndrome treated with metformin. Endocrinol Nutr. 2010;57(6):262-7. doi: 10.1016/j.endonu.2010.04.001, PMID 20547115.
Alves Ferreira M, Oliveira Gomes AP, Guimarães de Moraes AP, Ferreira Stringhini ML, Mota JF, Siqueira Guedes Coelho A et al. Green tea extract outperforms metformin in lipid profile and glycaemic control in overweight women: A double-blind, placebo-controlled, randomized trial. Clin Nutr ESPEN. 2017;22:1-6. doi: 10.1016/j.clnesp.2017.08.008, PMID 29415825.
Weijers RNM, Bekedam DJ. The metformin paradox. Curr Diabetes Rev. 2020;16(2):143-7. doi: 10.2174/1573399814666181119145750, PMID 30451115.
Lewandowski KC, Dąbrowska K, Brzozowska M, Kawalec J, Lewiński A. Metformin paradoxically worsens insulin resistance in SHORT syndrome. Diabetol Metab Syndr. 2019;11:81. doi: 10.1186/s13098-019-0477-z, PMID 31583022.
Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473-81. doi: 10.1111/dom.12854, PMID 27987248.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Hisham Alshadfan, Marai Alamri, Hyder Mirghani, Samar Aljohani, Mansuor Alanazi, Faisal Altemani, Majed Alqahtani, Ahmad Albalawi, Abdulaziz Humadi, Muhammad Nazrul Hakim Abdullah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
